- Home
- APLT vs FLYX Comparison
APLT vs FLYX Comparison
Compare APLT & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- FLYX
- Stock Information
- Founded
- APLT 2016
- FLYX 2015
- Country
- APLT United States
- FLYX United States
- Employees
- APLT N/A
- FLYX N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- FLYX Blank Checks
- Sector
- APLT Health Care
- FLYX Finance
- Exchange
- APLT Nasdaq
- FLYX Nasdaq
- Market Cap
- APLT 44.0M
- FLYX 39.4M
- IPO Year
- APLT 2019
- FLYX N/A
- Fundamental
- Price
- APLT $0.45
- FLYX $2.39
- Analyst Decision
- APLT Buy
- FLYX
- Analyst Count
- APLT 7
- FLYX 0
- Target Price
- APLT $6.10
- FLYX N/A
- AVG Volume (30 Days)
- APLT 1.6M
- FLYX 13.5K
- Earning Date
- APLT 08-11-2025
- FLYX 08-13-2025
- Dividend Yield
- APLT N/A
- FLYX N/A
- EPS Growth
- APLT N/A
- FLYX N/A
- EPS
- APLT N/A
- FLYX N/A
- Revenue
- APLT $265,000.00
- FLYX $335,427,000.00
- Revenue This Year
- APLT $415.60
- FLYX $28.47
- Revenue Next Year
- APLT $1,323.96
- FLYX $22.44
- P/E Ratio
- APLT N/A
- FLYX N/A
- Revenue Growth
- APLT N/A
- FLYX 5.38
- 52 Week Low
- APLT $0.30
- FLYX $1.79
- 52 Week High
- APLT $10.62
- FLYX $4.90
- Technical
- Relative Strength Index (RSI)
- APLT 53.55
- FLYX 47.90
- Support Level
- APLT $0.46
- FLYX $2.01
- Resistance Level
- APLT $0.54
- FLYX $2.59
- Average True Range (ATR)
- APLT 0.05
- FLYX 0.24
- MACD
- APLT -0.00
- FLYX 0.00
- Stochastic Oscillator
- APLT 53.66
- FLYX 55.16
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.